|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,507 GBX | +0.38% |
|
+0.10% | +3.88% |
| 10:20am | EU court criticizes Commission over handling of COVID vaccine contracts | RE |
| 07-16 | Emma Walmsley, CEO of GSK: Antimicrobial resistance, a public health issue | MT |
By Joe Hoppe
GSK said its sales rose, driven by growth in its best-selling shingles vaccine Shingrix and the launch of RSV vaccine Arexvy earlier last year, and raised its guidance for 2024.
The British pharmaceutical major posted sales of 8.05 billion pounds ($10.22 billion) for the fourth quarter of 2023, up from GBP7.33 billion the year prior and beating a Visible Alpha consensus of GBP7.61 billion.
Write to Joe Hoppe at joseph.hoppe@wsj.com
(END) Dow Jones Newswires
01-31-24 0233ET
| 1st Jan change | Capi. | |
|---|---|---|
| +3.88% | 79.3B | |
| +61.53% | 848B | |
| +33.05% | 627B | |
| -3.66% | 363B | |
| +15.06% | 318B | |
| +9.18% | 299B | |
| +13.66% | 243B | |
| +16.12% | 225B | |
| +15.67% | 179B | |
| +2.47% | 167B |
GSK PLC 
